Ensysce Biosciences

12/29/2022

We at Ensysce wish you a healthy and happy New Year!! And today, we are celebrating Happy National Resolutions Planning Day! Our resolution for 2023 is to continue the hard work to help those in pain. https://www.ensysce.com

12/28/2022

Today is a great day to be a good coach to someone, especially if they are struggling with opioid addiction. https://www.ensysce.com

12/27/2022

What does it mean-Ensysce’s PF614 with TAAPTM technology has earned FDA's “Fast Track” designation? It's designed to accelerate the process toward commercialization of select breakthrough therapies. https://en.wikipedia.org/wiki/Fast_track_(FDA)

12/22/2022

Ensysce Biosciences wishes you a very happy holiday season, one that is pain free and filled with much good health and happiness. https://www.ensysce.com

12/21/2022

We celebrate the Winter Solstice today, the shortest daylight of the year. We are reminded that even in pain’s darkness there is a brighter day ahead. A brighter day is our mission at Ensysce. https://ensysce.com

12/20/2022

Next gen pharma . . . as pharmaceutical companies seek to extend their proprietary patent & market positioning, abuse-deterrence & overdose are building blocks that are addressable in Ensysce technologies https://ensysce.com/partnering

12/15/2022

Happy National Bill of Rights Day! Introduced by James Madison, we celebrate America’s Constitution & respectfully suggest another right-those suffering from pain-the right to proper pain management https://www.archives.gov/news/topics/bill-of-rights

12/14/2022

Did you know… Ensysce is continuing to develop its TAAP™ technology for products to treat Opioid Use Disorder (OUD) and is supported by the National Institute for Drug Abuse (NIDA)? https://ensysce.com/our-strategy/

12/13/2022

Is the 1 to 10 pain scale obsolete? New ways to measure pain can help us communicate how bad it really is. New study tracks problems we face in having to communicate our pain on a subjective scale of 1 to 10.
https://www.newscientist.com/article/mg25634132-600-new-ways-to-measure-pain-can-help-us-communicate-how-bad-it-really-is/

12/08/2022

It’s great to hear that FDA is taking steps making nasal naloxone available OTC, to manage overdose. Long-term, solutions like Ensysce’s PF614 with TAAP and MPAR could be another step to reduce opioid abuse & overdose https://www.nbcnews.com/health/health-news/otc-naloxone-fda-opens-door-make-opioid-overdose-antidote-easier-acces-rcna57481

Over-the-counter versions of naloxone, a lifesaving drug that can reverse opioid overdoses, could begin appearing on pharmacy shelves as early as next year.

12/07/2022

MEET ENSYSCE: “We know our approaches cannot only provide advances in pain medicine but they also benefit our society. Our team is inspired by this combined mission.” Dave Humphrey – Chief Financial Officer (CFO) https://ensysce.com

12/06/2022

UPDATE: encouraging feedback & guidance from FDA for the Clinical Development Pathway for PF614, suggesting Ensysce’s approach appears reasonable to support a new drug application for an acute pain indication https://ir.ensysce.com/news/press-releases/detail/87/ensysce-biosciences-announces-fda-guidance-on-the-clinical